This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
Journal of Hematology & Oncology Open Access 20 March 2018
-
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Molecular Cancer Open Access 12 January 2018
-
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Journal of Hematology & Oncology Open Access 03 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. CAR-T field booms as next-generation platforms attract big players. Nat Biotechnol 33, 571–572 (2015). https://doi.org/10.1038/nbt0615-571
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0615-571
This article is cited by
-
Evolution of CAR T-cell immunotherapy in terms of patenting activity
Nature Biotechnology (2019)
-
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Molecular Cancer (2018)
-
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
Journal of Hematology & Oncology (2018)
-
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Journal of Hematology & Oncology (2017)
-
CAR-T cells forge ahead, Novartis reorganizes
Nature Biotechnology (2016)